Trials / Completed
CompletedNCT05494580
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2. Surufatinib is a novel small-molecule inhibitor that simultaneously targets tumor angiogenesis (via Vascular Endothelial Growth Factor Receptor \[VEGFR\]1, VEGFR 2, VEGFR3 and Fibroblast Growth Factor Receptor 1 \[FGFR1\]) and immune evasion (via Colony Stimulating Factor 1 Receptor \[CSF1R\]). In this trial, we aimed to evaluate the efficacy, safety and tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors.
Conditions
- Ovarian Cancer
- Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Fallopian Tube Carcinosarcoma
- Primary Peritoneal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pamiparib | Oral |
| DRUG | Surufatinib | Oral |
Timeline
- Start date
- 2022-09-22
- Primary completion
- 2024-06-20
- Completion
- 2026-01-31
- First posted
- 2022-08-10
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05494580. Inclusion in this directory is not an endorsement.